1. 339TiPPACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC. (24th November 2019) Authors: Wu, Y-L; Wang, L; Sendur, M A N; Kim, Y-C; Zhu, Z; Cheng, Y; Li, P; Qin, Y; Macpherson, E; Dennis, P A; Lu, S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗